Northeast Pharmaceutical Group Co., Ltd. Class A

As of June 30, 2026, Northeast Pharmaceutical Group Co., Ltd. Class A carries a market capitalization of 6.05B, placing it among publicly traded companies globally. Its enterprise value stands at 3.88B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Northeast Pharmaceutical Group Co., Ltd. Class A has 1.43B shares outstanding.

As of June 30, 2026, Northeast Pharmaceutical Group Co., Ltd. Class A trades at a trailing price-to-earnings ratio of 22.80. The price-to-sales ratio is 0.88, and the price-to-book ratio stands at 1.09.

As of June 30, 2026, Northeast Pharmaceutical Group Co., Ltd. Class A trades at an EV/EBITDA multiple of 14.70 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.57 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 14.70 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 3.88B versus a market cap of 6.05B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Northeast Pharmaceutical Group Co., Ltd. Class A maintains a current ratio of 1.14, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 33.19, indicating elevated leverage, while an interest coverage ratio of 5.84 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Northeast Pharmaceutical Group Co., Ltd. Class A posted a return on equity (ROE) of 4.85, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 2.59 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 1.94, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 4.62, useful for judging operating efficiency across full business cycles. The company generates approximately 1.18M in revenue per employee across its workforce of 5,786.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.28 indicates how many times Northeast Pharmaceutical Group Co., Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Northeast Pharmaceutical Group Co., Ltd. Class A recorded 67.19M in income tax expense. That works out to an effective tax rate of 24.29, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 276.67M, leaving 264.09M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, Northeast Pharmaceutical Group Co., Ltd. Class A's stock has declined approximately 22.05% over the past 52 weeks. The 50-day moving average sits at 4.84, while the 200-day moving average is 4.94.

Over the twelve months ended June 30, 2026, Northeast Pharmaceutical Group Co., Ltd. Class A generated 6.84B in revenue and converted that into 264.09M in net income, yielding earnings per share of 0.15. EBITDA reached 263.53M, while operating income came in at 481.68M.

As of June 30, 2026, Northeast Pharmaceutical Group Co., Ltd. Class A holds 4.17B in cash and equivalents against 1.88B in total debt, resulting in a net debt position of -2.24B. Total book value stands at 5.53B, with working capital of 1.05B providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Northeast Pharmaceutical Group Co., Ltd. Class A posted a gross margin of 36.16, reflecting its pricing power and cost economics. The operating margin of 7.05 and net profit margin of 3.86 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Northeast Pharmaceutical Group Co., Ltd. Class A paid dividends of 0.18 per share. The dividend payout ratio of 160.95 exceeds 100%, meaning the company is distributing more than it earns and funding the dividend from cash reserves, asset sales, or borrowing, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield is negative at -0.47, meaning Northeast Pharmaceutical Group Co., Ltd. Class A raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Northeast Pharmaceutical Group Co., Ltd. Class A's most recent stock split took place on May 20, 2020 with a 100:149 split ratio.

As of June 30, 2026, Northeast Pharmaceutical Group Co., Ltd. Class A has an Altman Z-Score of 1.42, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.